Cyclerion Therapeutics Inc.

The momentum for this stock is not very good. Cyclerion Therapeutics Inc. is a mediocre stock to choose.

News

Regina Graul, Ph.D., Promoted to Chief Executive Officer

Globe Newswire CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced that Regina Graul, Ph.D., has been promoted to Chief Executive Officer, President...\n more…

Cyclerion Therapeutics (NASDAQ:CYCN) Trading Down 10.2%

Zolmax Cyclerion Therapeutics, Inc. (NASDAQ:CYCN - Get Free Report)'s stock price was down 10.2% during mid-day trading on Monday . The stock traded as low as $2.00 and last traded at $2.29. Approximately...\n more…

CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q1 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nCyclerion Therapeutics just reported results for the first quarter of 2024.\nThe post CYCN Stock Earnings: Cyclerion Therapeutics...\n more…

CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nCyclerion Therapeutics just reported results for the fourth quarter of 2023.\nThe post CYCN Stock Earnings: Cyclerion Therapeutics...\n more…

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Sees Significant Growth in Short Interest

Zolmax Cyclerion Therapeutics, Inc. (NASDAQ:CYCN Get Free Report) saw a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 16,100...\n more…

Cyclerion Therapeutics appoints Graul as President

Seeking Alpha - Healthcare Cyclerion Therapeutics appoints Graul as President...\n more…